Humanized Anti-MUC16 Recombinant V-kappa Antibody (TAB-H63)

Customer Review

There are currently no Customer reviews or questions for TAB-H63. Click the button above to contact us or submit your feedback about this product.

Citations

1. Rasoulouniriana, Diana, et al. "T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors." Cancer Immunology Research 11.6 (2023): 792-809. https://doi.org/10.1158/2326-6066.CIR-22-0423
   The study focused on engineering a modified FcgRI receptor for T cells, aiming to enhance their antibody-dependent cytotoxicity (ADCC) against solid tumors. This new receptor allows T cells to target tumor cells using antibodies, demonstrating effective and specific cytotoxicity only in the presence of appropriate antibodies. The engineered T cells, tested in both immunocompetent and immunodeficient mice, showed significant tumor eradication while secreting lower levels of cytokines compared to traditional CAR T cells, thus enhancing their safety profile. This technology offers a versatile approach, enabling the same engineered T cells to target different tumors by simply changing the injected antibody.
   Creative Biolabs contributed by providing several critical antibodies for the study. Specifically, Creative Biolabs supplied Sofituzumab (Cat#: TAB-H63) and Necitumumab (Cat#: TAB-119). These antibodies were essential for testing the ADCC capabilities of the modified T cells, as they facilitated the targeting of specific tumor antigens, demonstrating the versatility and efficacy of the engineered T cells in preclinical models.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-H63, RRID: AB_3112040)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Sofituzumab Vedotin Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Sofituzumab Vedotin.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "MUC16"

Select a product category from the dropdown menu below to view related products.